AACR 2026: Precision Biologics says it found a new weak spot in AML for CAR-NK therapy

Precision Biologics, Inc. said it will present new preclinical data at the American Association for Cancer Research Annual Meeting in San Diego on April 19, 2026, identifying truncated Core 1 O-glycans recognized by NEO-201 as a potential new antigen target for CAR-NK therapy in acute myeloid leukemia. The abstract, already published in Cancer Research, describes activity across several AML cell lines and suggests the antigen may be largely absent from early hematopoietic progenitors, which is exactly the kind of selectivity developers have been chasing in leukemia cell therapy for years. That matters because AML remains one of the most difficult blood cancers to target immunologically without also damaging normal marrow function. Precision Biologics is not presenting clinical data yet, but it is trying to position glycan-directed cell therapy as a fresh angle in a field that has spent years bumping into the same antigen wall.

Why is finding a safer AML antigen still one of the hardest problems in cell therapy development?

The core issue in AML has never been a shortage of scientific ambition. It has been target quality. Many candidate surface markers in AML also show up on normal hematopoietic stem cells or progenitors, which makes “precision killing” less precise than anyone would like. The AACR abstract from Precision Biologics directly addresses that bottleneck by arguing that the NEO-201-recognized truncated Core 1 O-glycan is present across multiple AML subtypes while remaining minimal or absent on CD34-positive hematopoietic stem cells and only low on early myeloid progenitors. If that profile ultimately holds up in broader patient samples and then in clinical testing, the target could become interesting not because it is flashy, but because it might be comparatively usable. In AML, boringly selective can be far more valuable than excitingly toxic.

That backdrop also explains why this poster could attract attention despite still being preclinical. Acute myeloid leukemia continues to carry poor long-term outcomes. The National Cancer Institute’s SEER data lists the five-year relative survival rate at 32.9% based on 2015 to 2021 data, while the American Cancer Society estimates 22,720 new AML cases and 11,500 deaths in the United States in 2026. In other words, the medical need is still glaringly obvious, and the field is still open to novel targeting logic.

What does the Precision Biologics AACR abstract actually show for NEO-201 in AML models?

The abstract reports that the antigen was expressed at more than 40% in six of ten AML cell lines representing different molecular subtypes, including FLT3-ITD-mutated, MLL-rearranged, biphenotypic, and core-binding factor leukemias. Expression ranged from 41% to 100% in positive lines, with THP-1, MOLM-14, MV4-11, U-937, HL-60, and ME-1 all showing measurable binding. In cytotoxicity assays, NEO-201-based CAR-NK cells showed antigen-dependent killing, including 61% lysis of THP-1, 45% of HL-60, and 40% of MOLM-14 targets at a 10:1 effector-to-target ratio. Those are not trivial numbers for an early-stage poster, particularly because the authors also say activity was seen even in lines with lower antigen density.

Just as important is where the antigen was not strongly found. According to the abstract, expression was minimal or absent on CD34-positive hematopoietic stem cells at 0% to 1%, low on early myeloid progenitors at 10% to 15%, and enriched in mature neutrophils at roughly 99%. That pattern immediately creates both excitement and caution. Excitement, because sparing early progenitors could make the target more clinically practical than many AML antigens. Caution, because heavy expression in mature neutrophils raises a clear on-target, off-tumor question that future studies will need to explore with more nuance than a conference abstract can provide.

Why could glycan-directed CAR-NK therapy matter more than another conventional AML target story?

What makes this story stand out is not just the CAR-NK angle. It is the glycan biology. Precision Biologics is effectively arguing that AML-restricted or AML-enriched glycans may be an underexplored target class compared with protein antigens that have already been heavily mined. The company’s NEO-201 antibody was previously associated with truncated O-glycan recognition in solid tumors, and the AACR abstract extends that logic into hematologic malignancies. That creates a potentially differentiated strategic narrative: rather than joining the crowd around better-known AML antigens, Precision Biologics is trying to widen the map itself.

That said, a new target class does not automatically become a clinically useful one. Glycan biology can be attractive because tumor-associated glycosylation changes are real and biologically meaningful, but these targets can also become messy when expression patterns vary by disease state, maturation stage, tissue context, or assay method. The abstract is encouraging, but it is still an abstract. Investors and industry watchers should treat this as an early signal of platform direction, not proof of therapeutic inevitability.

What are the biggest execution risks for Precision Biologics after AACR 2026?

The first risk is translational durability. Cell-line data are useful, but AML is notoriously heterogeneous in real patients. Precision Biologics will need to show that truncated Core 1 O-glycan expression is not just visible in selected models, but meaningfully prevalent in clinically relevant AML populations, including relapsed and refractory disease.

The second risk is safety characterization. The low expression on early progenitors is encouraging, but the strong expression on mature neutrophils means developers will need a convincing strategy around hematologic toxicity, infection risk, dosing logic, and potentially transient cytopenias. In blood cancers, safety questions do not politely wait until Phase 2.

The third risk is manufacturing and platform differentiation. CAR-NK has promise as an alternative to CAR-T because of its potential allogeneic flexibility and safety advantages, but it still faces the familiar commercial questions of persistence, scalability, and durable in vivo activity. Precision Biologics therefore has two jobs, not one: validate the target and validate the delivery platform.

What happens next for Precision Biologics if this AML target story keeps gaining traction?

The near-term next step is straightforward. Precision Biologics needs to turn conference interest into a more complete translational package, ideally with expanded patient-sample characterization, stronger in vivo evidence, and a clearer safety story. If those data develop well, the company may be able to position NEO-201-directed CAR-NK as a differentiated candidate in AML, particularly for high-risk or relapsed settings where conventional options remain inadequate.

For the wider field, this poster is a reminder that AML immunotherapy may still need new target logic more than it needs louder platform branding. The race is not simply about building stronger cell therapies. It is about finding targets that let those therapies do their job without destroying the marrow in the process. Precision Biologics is arguing that truncated O-glycans could be part of that answer. It is an early claim, but it is at least pointing at the right problem. And in AML, that already puts it ahead of a surprising amount of noise.

What are the key takeaways from Precision Biologics’ AACR 2026 AML CAR-NK target update?

• Precision Biologics used AACR 2026 to introduce truncated Core 1 O-glycans recognized by NEO-201 as a potential new antigen target for CAR-NK therapy in acute myeloid leukemia.
• The significance of the update lies in target selectivity, which remains one of the biggest barriers in AML immunotherapy because many known antigens are also expressed on healthy hematopoietic cells.
• The preclinical data suggest the target is present across multiple AML subtypes, which could make the approach relevant beyond a narrow molecular niche.
• NEO-201-based CAR-NK cells showed antigen-dependent killing in AML cell-line models, giving Precision Biologics an early efficacy signal worth watching.
• The reported minimal expression on CD34-positive hematopoietic stem cells is one of the most important parts of the story because it hints at a potentially safer targeting profile.
• At the same time, the strong expression seen in mature neutrophils means safety and on-target off-tumor effects will remain a central development question.
• This is still an early-stage research story, not a clinical proof point, so the poster should be viewed as a translational signal rather than a near-term therapeutic breakthrough.
• The company’s differentiation comes from its glycan-targeting strategy, which gives it a less crowded angle in AML cell therapy compared with developers pursuing more familiar protein antigens.
• The next major milestone will be stronger validation in broader patient samples and additional translational work that can support movement toward clinical development.
• For the AML field more broadly, the update reinforces that the next wave of progress may depend as much on discovering better targets as on improving the cell therapy platform itself.